One, at least Moderna is absolutely within the capability of many, many LMIC. (Pfizer/BioNTech, not so much). Two, if rich countries stretch Moderna/Pfizer more, that's a lot more of the rest for LMIC. Doesn't resolve question but equity side has that to consider.
-
-
(Speaking of Gates Foundation. Forgot to mention. Here’s Klugman of Gates, who needs no introduction about his credentials and experience with vaccines and vaccination.)https://twitter.com/findingpneumo/status/1339556859473227778 …
-
And Klugman’s response to UK’s decision. (My sense is people like him, with deep global experience and working with vulnerable populations, are a lot more experienced with such thorny trade-offs which are newer to experts from wealthy countries of great privilege).https://twitter.com/findingpneumo/status/1344268340857081858 …
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.